Make an enquiry
Refer a patient
Patient Portal
HCP Logout

We noticed you are on our AU page. Want to switch regions? Choose from the options:

UK
ES
Find a centre
Find a doctor
Make an enquiry
Refer a patient

We noticed you are on our AU page. Want to switch regions? Choose from the options:

UK
ES
Find a centre
Find a doctor
2022-01-18T00:00:00.000+00:00
Ongoing

SEAMARK – C4221022

SEAMARK – C4221022
Colorectal cancer

Phase 2, randomized, open-label study of encorafenib and cetuximab plus pembrolizumab versus pembrolizumab alone in participants with previously untreated BRAF V600E-mutant, MSI H/DMMR metastatic colorectal cancer.

Phase 2, randomized, open-label study of encorafenib and cetuximab plus pembrolizumab versus pembrolizumab alone in participants with previously untreated BRAF V600E-mutant, MSI H/DMMR metastatic colorectal cancer.

Trial overview

Clinical Area

Medical Oncology

Disease / Condition

Colorectal

Study Phase

II

Trial Identifiers

Registration number: NCT05217446

https://clinicaltrials.gov/study/NCT05217446

GenesisCare Location(s)

North Shore 

North Shore  :::
Principal Investigator(s)

A/Prof Connie Diakos

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.